Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 12:15:1177271920964108.
doi: 10.1177/1177271920964108. eCollection 2020.

Clusterin as a Potential Biomarker of Obesity-Related Alzheimer's Disease Risk

Affiliations
Review

Clusterin as a Potential Biomarker of Obesity-Related Alzheimer's Disease Risk

David Bradley. Biomark Insights. .

Abstract

Over 35% of the adult US population is obese. In turn, excess adiposity increases the risk of multiple complications including type 2 diabetes (T2D), insulin resistance, and cardiovascular disease; yet, obesity also independently heightens risk of Alzheimer's Disease (AD), even after adjusting for other important confounding risk factors including blood pressure, sociodemographics, cholesterol levels, smoking status, and Apolipoprotein E (ApoE) genotype. Among patients over the age of 65 with dementia, 37% have coexisting diabetes, and an estimated 7.3% of cases of AD are directly attributable to midlife obesity. Clusterin, also known as apolipoprotein J (ApoJ), is a multifunctional glycoprotein that acts as a molecular chaperone, assisting folding of secreted proteins. Clusterin has been implicated in several physiological and pathological states, including AD, metabolic disease, and cardiovascular disease. Despite long-standing interest in elucidating clusterin's relationship with amyloid beta (Aβ) aggregation/clearance and toxicity, significant knowledge gaps still exist. Altered clusterin expression and protein levels have been linked with cognitive and memory function, disrupted central nervous system lipid flux, as well as pathogenic brain structure; and its role in cardiometabolic disease suggests that it may be a link between insulin resistance, dyslipidemia, and AD. Here, we briefly highlight clusterin's relevance to AD by presenting existing evidence linking clusterin to AD and cardiometabolic disease, and discussing its potential utility as a biomarker for AD in the presence of obesity-related metabolic disease.

Keywords: Alzheimer’s Disease; adipose tissue; amyloid beta; clusterin.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests:The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Summary of hypothesized mechanisms (labeled 1-3) responsible for clusterin-mediated amyloid beta (Aβ) deposition. Abbreviations: ApoA1, apolipoprotein A1; ApoE, apolipoprotein E; BBB, blood brain barrier; CSF, cerebrospinal fluid; HDL, high density lipoprotein.

Similar articles

Cited by

References

    1. Alzheimer’s Association. Alzheimer’s disease facts and figures [Ebook]. https://www.alz.org/documents_custom/2018-facts-and-figures.pdf. Accessed June 20, 2020.
    1. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80:1778-1783. - PMC - PubMed
    1. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45:1452-1458. - PMC - PubMed
    1. Barnard ND, Bush AI, Ceccarelli A, et al. Dietary and lifestyle guidelines for the prevention of Alzheimer’s disease. Neurobiol Aging. 2014;35 Suppl 2:S74-S78. - PubMed
    1. Bendlin BB, Carlsson CM, Gleason CE, et al. Midlife predictors of Alzheimer’s disease. Maturitas. 2010;65:131-137. - PMC - PubMed